Durable, potentially curative therapies for genetic disorders and cancer have arrived. Short—even single dose—treatment regimens yield lasting health benefits, but large single payments will challenge the current reimbursement system.
In this virtual workshop the FoCUS Project will help you explore the impact of cell and gene therapies on your health benefit plans, survey the risks, and learn about solutions.
June 17, 2021
11:00am – 3:00pm Eastern via Web conference
Registration is free
This intensive 1-day virtual workshop will help you:
- Understand how these therapies are different
- Explore new solutions and support resources
- Discover actionable and affordable steps to ensure sustainable coverage and access
Ideal for:
- Self-insured employer health benefits and finance professionals
- Other advisors and partners such as self-insured employer brokers, consultants and stop-loss carriers

Workshop archive
Workshop recordings
Highlights from the workshop are shared here, and full workshop session recordings are included below in the agenda.
Self-Insured Employers Workshop Presentation
You can now download the archive of decks presented in the workshop.
New White Paper: Emerging Market Solutions
Our research and analysis based on a survey of solution providers shows what's available, what's missing, and what might fit your needs.
Precision Financing Strategies Toolkit
Learn more about the challenges, potential solutions, and with interactive calculators, how to assess your risk and plan for the future,
Agenda
Welcome and introductions
Framing the issues
Introduction to FoCUS, and to the unique challenges/risks cell & gene therapies present to self-insured employers.
Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project
Framing the solutions
Precision financing solutions, including the free Paying for Cures online toolkit, to address risks of currently approved treatments and near-term pipeline of expected products.
Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management
Implications of cell & gene therapies on stop-loss coverage
Mehb Khoja, Chief Actuary at BCS Financial and President of Medical Risk Managers
New commercial solutions
Michelle Harika, Chief Clinical Officer for Equity Healthcare
Panel & Discussion
Actions self-insured employers can take today
Mark Trusheim, MIT NEWDIGS and moderator
Michelle Harika, Chief Clinical Officer for Equity Healthcare
Mehb Khoja, Chief Actuary at BCS Financial and President of Medical Risk Managers
Cynthia Pigg, Senior Vice President, AON
Luke Prettol, Lead Benefits Strategy Consultant at AT&T
Thanks and conclusion
Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project
Speakers

Jane F. Barlow, MD, MBA, MPH
CEO, Jane Barlow & Associates;
EVP and Chief Clinical Officer, Real Endpoints;
Senior Advisor, MIT Center for Biomedical Innovation, NEWDIGS

Michelle Harika, PharmD
Chief Clinical Officer for Equity Healthcare

Mehb Khoja
Chief Actuary at BCS Financial and President of Medical Risk Managers

Cynthia J. Pigg, BSMT, BSPharm, MHA, FAMCP
Senior Vice President, Commercial Market Leader, Pharmacy, AON

Luke Prettol, CEBS HCS PHR
Lead Benefits Strategy Consultant at AT&T

Mark Trusheim, MS
Strategic Director, NEWDIGS;
Visiting Scientist, Sloan School of Management,
Massachusetts Institute of Technology
Registration
June 17, 11:00am – 3:00pm
Zoom Web conference
Registration is free